|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table 1** Comparison between patients with and without chloroquine therapy in Changsha after propensity score matching | | | | |
|  | Chloroquine (n = 25) | Without Chloroquine (n = 25) | Difference (95% CI) | *P* |
| Age (years) | 51 (41 to 62) | 46 (38 to 67) | -3 (-12 to 8) | 0.724 |
| Male gender | 11 (44.0%) | 11 (44.0%) | 0 (-25.7 to 25.7) | 1.000 |
| Hypertension | 0 (0) | 0 (0) | 0 (-13.3 to 13.3) | 1.000 |
| Blood leukocyte count, ×109/L | 4.5 (3.3 to 5.5) | 4.8 (3.7 to 5.7) | 0.4 (-0.5 to 1.2) | 0.404 |
| Neutrophil count, × 10⁹/L | 2.7 (1.8 to 3.4) | 3.1 (2.3 to 3.7) | 0.5 (-0.2 to 1.0) | 0.135 |
| Lymphocyte count, × 10⁹/L | 1.3 (1.0 to 1.7) | 1.2 (0.8 to 1. 8) | -0.1 (-0.4 to 0.3) | 0.873 |
| Alanine aminotransferase, U/L | 18.3 (11.8 to 23.0) | 14.8 (12.1 to 22.6) | -1.8 (-5.9 to 2.8) | 0.574 |
| Aspartate aminotransferase, U/L | 23.6 (17.3 to 29.5) | 25.5 (17.4 to 30.4) | 0.4 (-4.2 to 5.4) | 0.884 |
| Total bilirubin, μmol/L | 11.3 (8.0 to 16.2) | 11.5 (8.6 to 15.8) | 0.2 (-2.6 to 2.9) | 0.946 |
| Albumin, g/L | 40.9 (36.8 to 42.9) | 36.5 (35.1 to 41.6) | -2.2 (-5.4 to 0.6) | 0.132 |
| Blood urea nitrogen, mmol/L | 4.4 (3.0 to 5.1) | 4.5 (3.4 to 5.0) | 0.2 (-0.6 to 1.1) | 0.635 |
| Creatinine, μmol/L | 49.9 (39.3 to 65.4) | 48.9 (39.4 to 57.7) | -3.0 (-11.0 to 5.7) | 0.616 |
| Creatine kinase, U/L | 68.3 (53.6 to 110.2) | 46.4 (35.8 to 89.9) | -14.0 (-32.0 to 7.7) | 0.528 |
| Lactose dehydrogenase, U/L | 154.3 (135.2 to 201.8) | 154.2 (125.0 to 214.6) | -5.5 (-29.9 to 23.5) | 0.679 |
| D-dimer ≥ 0.05 mg/L | 11 (44.0%) | 7 (28.0%) | -16.0 (-39.4 to 10.2) | 0.239 |
| Procalcitonin ≥ 0.05 ng/L | 7 (28.0%) | 7 (28.0%) | 0 (-23.9 to 23.9) | 1.000 |
| C-reactive protein level ≥ 10 mg/L | 13 (52.0%) | 12 (48.0%) | -4.0 (-29.4 to -22.2) | 0.777 |
| Abnormal CT findings | 22 (88.0%) | 24 (96.0%) | 8.0 (-9.4 to 26.3) | 0.297 |
| CT severity score | 4 (2 to 8) | 4 (2 to 7) | 0 (-2 to 2) | 0.861 |
| Combined treatments after admission | |  |  |  |
| Nonspecific antiviral therapy | 24 (96.0%) | 23 (92.0%) | -4.0 (-21.3 to 12.6) | 0.552 |
| Interferon α | 9 (36.0%) | 12 (48.0%) | 12.0 (-14.5 to 36.3) | 0.390 |
| Intravenous antibiotics | 11 (44.0%) | 16 (64.0%) | 20.0 (-7.2 to 43.4) | 0.156 |
| Severe pneumonia | 0 (0) | 3 (12.0%) | 12.0 (-3.5 to 30.0) | 0.074 |
| Any adverse events | 12 (48.0%) | 11 (44.0%) | -4.0 (-29.4 to 22.1) | 0.777 |
| ≥ Grade 3 adverse events | 5 (20.0%) | 3 (12.0%) | -8.0 (-28.7 to 13.1) | 0.440 |
| Abbreviations: CI, confidence interval; CT computed tomography. | | | | |

**Supplementary Figure 1** Chest computed tomography images of a 63-year-old female patient with severe COVID-19 pneumonia on admission. A, Chest computed tomography images obtained on January 24, 2020, show bilateral ground glass opacity with lung CT score of 15 on day 10 after symptom onset. B, Images on February 2, 2020, show the partial absorption and local progression of ground glass opacity with patchy of consolidation after adjuvant treatment.

**Supplementary Figure 2** Dynamic profile of laboratory and imaging findings between hypertensive patients on ACEI/ARB therapy and on non-ACEI/ARB therapy. Timeline bar graphs illustrate the laboratory (A) and imaging (B) parameters in 65 patients based on the days after admission. \* *P* < .05 for patients on ACEI/ARB therapy vs patients on non-ACEI/ARB therapy.



**Supplementary Figure 1**



**Supplementary Figure 2**